YPL185W Antibody

What is YPL185W and why would researchers study it?

YPL185W is a yeast open reading frame (ORF) that encodes a protein of currently unknown function in Saccharomyces cerevisiae. Researchers study this protein to expand our understanding of yeast proteomics and functional genomics. Despite its uncharacterized function, investigating YPL185W contributes to comprehensive mapping of yeast protein networks and may reveal novel biological pathways. The antibody serves as a critical tool for detecting, localizing, and studying this protein's expression patterns and interactions within yeast cells.

What types of YPL185W antibodies are available for research?

YPL185W antibodies are available in both monoclonal and polyclonal formats. Monoclonal antibodies offer high specificity and reproducibility between batches, while polyclonal antibodies may recognize multiple epitopes but exhibit greater batch-to-batch variability. The immunogens typically used for YPL185W antibody production include recombinant YPL185W protein or synthetic peptides corresponding to specific sequences within the protein. Researchers should select the antibody type based on their specific experimental requirements and the degree of specificity needed.

What are the validated applications for YPL185W antibodies?

YPL185W antibodies have been validated for several standard laboratory techniques:

These applications provide complementary approaches to detect and characterize YPL185W protein expression, localization, and interactions in research settings. Validation across multiple techniques increases confidence in experimental results and helps address potential artifacts associated with any single method.

How should I validate a YPL185W antibody before use in my experiments?

To validate a YPL185W antibody, implement a multi-step approach:

• Begin with positive control experiments using yeast lysates known to express YPL185W protein.

• Include negative controls using YPL185W knockout yeast strains to confirm specificity.

• Perform Western blot analysis to verify a single band of appropriate molecular weight (~45 kDa).

• Test antibody performance in your specific experimental conditions and sample types.

• If possible, compare results using different antibodies targeting the same protein (orthogonal validation) .

This systematic validation approach aligns with the "five pillars" of antibody characterization described in the literature and helps ensure reliable experimental outcomes by confirming both specificity and functionality in your particular experimental system .

How can I optimize YPL185W antibody performance for challenging experimental conditions?

Optimizing YPL185W antibody performance requires systematic adjustment of multiple parameters:

For Western blotting:

• Test different blocking agents (BSA vs. milk) to reduce background.

• Optimize primary antibody concentration (typically start with 1:500-1:2000 dilutions).

• Adjust incubation time and temperature (overnight at 4°C vs. 1-2 hours at room temperature).

• Consider membrane type (PVDF vs. nitrocellulose) based on protein properties.

• Test different antigen retrieval methods if signal is weak.

For immunofluorescence:

• Compare fixation methods (paraformaldehyde vs. methanol) as they affect epitope accessibility.

• Optimize permeabilization conditions to maintain cellular structures while allowing antibody access.

• Test different antibody concentrations and incubation times.

• Consider signal amplification systems for low-abundance targets.

Document all optimization steps methodically to establish reproducible protocols for future experiments with YPL185W antibody.

What strategies can address epitope accessibility issues with YPL185W antibody?

Epitope accessibility can significantly impact YPL185W antibody performance across different applications. To address this:

• Understand the nature of your epitope - whether it's linear or conformational - as this determines which applications will be most successful.

• For conformational epitopes, minimize denaturation steps in protocols when native structure recognition is required.

• For linear epitopes that may be masked in folded proteins, ensure adequate denaturation for exposure.

• Consider epitope retrieval methods for fixed samples, such as heat-induced or enzymatic antigen retrieval.

• Test both reducing and non-reducing conditions in Western blotting if disulfide bonds might affect epitope structure.

• Be aware that post-translational modifications near the epitope may interfere with antibody binding .

Different experimental conditions alter protein conformation and epitope exposure, requiring optimization for each specific application to ensure consistent YPL185W detection.

How can I use YPL185W antibodies to investigate protein-protein interactions?

YPL185W antibodies serve as valuable tools for investigating protein-protein interactions through several methodological approaches:

• Co-immunoprecipitation (Co-IP):

  • Use YPL185W antibody coupled to agarose or magnetic beads to precipitate the target protein.

  • Analyze co-precipitating proteins by mass spectrometry or Western blotting.

  • Include appropriate controls (IgG control, lysates from YPL185W knockout strains).

• Proximity Ligation Assay (PLA):

  • Combine YPL185W antibody with antibodies against potential interacting partners.

  • PLA signals occur only when proteins are in close proximity (<40 nm).

  • Quantify interaction frequency in different cellular compartments or conditions.

• FRET/FLIM analysis:

  • Use fluorophore-conjugated YPL185W antibodies in combination with differently labeled antibodies.

  • Energy transfer occurs only at molecular interaction distances.

• Pull-down validation:

  • Confirm interactions identified through other methods like yeast two-hybrid screens.

  • Use recombinant tagged-YPL185W protein to pull down interacting partners.

These approaches provide complementary evidence for physical associations between YPL185W and other cellular proteins, offering insights into its biological function.

What are the considerations for using YPL185W antibody in cross-species studies?

When using YPL185W antibody for cross-species studies, several critical factors must be evaluated:

• Epitope conservation analysis:

  • Perform sequence alignment of the epitope region across target species.

  • Higher sequence homology increases the likelihood of cross-reactivity.

  • Even single amino acid differences in critical binding residues can eliminate reactivity.

• Empirical validation:

  • Test the antibody against lysates from each species of interest.

  • Verify correct molecular weight and band pattern in Western blots.

  • For immunostaining, confirm expected subcellular localization patterns.

• Potential limitations:

  • YPL185W antibody is primarily validated for S. cerevisiae, with cross-reactivity in other species dependent on epitope conservation.

  • Cross-reactivity doesn't guarantee identical specificity across species.

  • Non-specific binding may occur to homologous proteins in distant species.

• Alternative approaches:

  • Consider species-specific antibodies when available.

  • Epitope engineering may enhance cross-species utility in some cases.

How can I troubleshoot weak or absent signals when using YPL185W antibody?

When encountering weak or absent signals with YPL185W antibody, implement this structured troubleshooting approach:

• Sample preparation issues:

  • Verify protein extraction efficiency with a control antibody against a housekeeping protein.

  • Ensure protease inhibitors were included during extraction.

  • Check protein quantification method for accuracy.

• Technical parameters:

  • Increase antibody concentration (reduce dilution) in a systematic manner.

  • Extend primary antibody incubation time (overnight at 4°C).

  • Enhance detection sensitivity (longer exposure, more sensitive substrates).

  • Optimize blocking conditions to improve signal-to-noise ratio.

• Antibody-specific factors:

  • Confirm antibody reactivity hasn't been compromised by improper storage.

  • Verify the antibody recognizes the specific form of your protein (native vs. denatured).

  • Test alternative antibodies targeting different epitopes of YPL185W.

• Biological considerations:

  • Confirm expression levels of YPL185W in your specific yeast strain and growth conditions.

  • Consider whether experimental manipulations might affect expression.

  • Verify that the epitope is accessible in your experimental system .

Document all troubleshooting steps methodically to identify the most effective solution and establish a reproducible protocol.

What controls are essential when using YPL185W antibody in various applications?

Implementing appropriate controls is critical for interpreting results with YPL185W antibody:

For Western blotting:

• Positive control: Lysate from wild-type yeast known to express YPL185W.

• Negative control: Lysate from YPL185W knockout strain.

• Loading control: Antibody against a housekeeping protein (e.g., GAPDH, actin).

• Primary antibody control: Omit primary antibody but include secondary.

• Secondary antibody control: Omit secondary antibody to check for autofluorescence .

For immunoprecipitation:

• Input control: Sample of starting material before immunoprecipitation.

• IgG control: Non-specific IgG of same species and isotype.

• Bead-only control: Precipitation matrix without antibody.

• Competitive peptide control: Block antibody with excess immunizing peptide .

For immunofluorescence:

• Secondary-only control: Omit primary antibody to assess non-specific binding.

• Knockout control: YPL185W deletion strain to verify specificity.

• Peptide competition: Pre-incubate antibody with immunizing peptide.

• Counterstaining with organelle markers to verify subcellular localization .

These controls collectively establish specificity, rule out artifacts, and enable accurate interpretation of experimental results.

How should YPL185W antibody be stored and handled to maintain optimal performance?

Proper storage and handling of YPL185W antibody are essential for maintaining its activity and specificity:

Storage recommendations:

• Store antibody aliquots at -20°C for long-term preservation.

• Avoid repeated freeze-thaw cycles by preparing single-use aliquots.

• For working dilutions, store at 4°C with preservative (e.g., 0.02% sodium azide) for up to 1 month.

• Monitor storage temperature consistency to prevent degradation.

Handling guidelines:

• Centrifuge briefly before opening vials to collect liquid at the bottom.

• Use sterile technique when accessing antibody stocks.

• Maintain cold chain during all handling steps.

• Do not vortex antibodies; mix by gentle inversion or pipetting.

• Use non-stick tubes for dilute antibody solutions to prevent adsorption.

Working dilution preparation:

• Prepare fresh working dilutions in high-quality, filtered buffer solutions.

• Include carrier protein (BSA 1-5%) in very dilute solutions to prevent adsorption losses.

• Document preparation date and conditions for traceability.

Following these practices will extend antibody shelf-life and ensure consistent performance across experiments.

How can I quantitatively assess YPL185W antibody specificity and sensitivity?

Quantitative assessment of YPL185W antibody performance requires systematic evaluation of multiple parameters:

For specificity assessment:

• Signal-to-noise ratio calculation:

  • Compare signal intensity between wild-type and YPL185W knockout samples.

  • Calculate specific signal as: (WT signal - KO signal) / KO signal.

  • Values >10 indicate high specificity.

• Cross-reactivity profiling:

  • Test against a panel of related yeast proteins.

  • Calculate percent cross-reactivity as: (signal with related protein / signal with target) × 100%.

  • Specificity is inversely proportional to cross-reactivity percentage .

For sensitivity assessment:

• Limit of detection (LOD) determination:

  • Prepare serial dilutions of purified recombinant YPL185W protein.

  • Plot standard curve and calculate concentration yielding signal 3× above background.

  • The ELISA EC₅₀ value of 2.5 nM provides a reference point for sensitivity expectations.

• Dynamic range evaluation:

  • Test antibody performance across a concentration range of target protein.

  • Determine linear response range where signal proportionally increases with concentration.

  • Document upper and lower detection limits for quantitative applications .

These quantitative assessments should be performed for each application (Western blot, ELISA, immunofluorescence) as performance may vary across techniques.

How can YPL185W antibody contribute to functional genomics studies in yeast?

YPL185W antibody serves as a valuable tool in functional genomics through multiple experimental approaches:

• Protein localization studies:

  • Use immunofluorescence to determine subcellular compartmentalization.

  • The documented nuclear/cytoplasmic localization provides clues about potential function.

  • Combine with cellular fractionation and Western blotting for quantitative distribution analysis.

• Expression profiling:

  • Track YPL185W protein levels under different growth conditions or stress responses.

  • Correlate protein expression with transcriptomic data to identify post-transcriptional regulation.

  • Analyze expression changes during cell cycle progression or developmental stages.

• Interaction network mapping:

  • Utilize co-immunoprecipitation to identify binding partners.

  • Build protein-protein interaction networks to infer functional relationships.

  • Validate physical interactions through reciprocal pulldowns.

• Genetic interaction validation:

  • Compare YPL185W protein levels in genetic backgrounds with synthetic lethal/sick interactions.

  • Assess protein localization changes in mutant strains to identify functional dependencies.

These approaches collectively contribute to deciphering the biological role of this currently uncharacterized protein in yeast cellular biology.

What challenges exist in reproducing YPL185W antibody experiments across different laboratories?

Reproducing experiments with YPL185W antibody across laboratories faces several significant challenges:

• Antibody variability issues:

  • Batch-to-batch variations, particularly with polyclonal antibodies.

  • Limited information about epitope specificity in commercial antibodies.

  • Hybridoma-derived monoclonals show greater consistency than polyclonals .

• Protocol standardization gaps:

  • Differences in sample preparation (lysis buffers, protease inhibitors).

  • Variations in blocking agents and incubation conditions.

  • Detection system sensitivities (ECL formulations, imaging equipment).

• Reporting inconsistencies:

  • Incomplete documentation of antibody source, catalog number, and dilution.

  • Missing validation data in publications.

  • Limited sharing of detailed protocols and troubleshooting strategies .

• Solution approaches:

  • Use recombinant antibodies when available for greater consistency.

  • Implement the "five pillars" validation approach for standardized characterization.

  • Share detailed protocols including buffer compositions and processing times.

  • Report Research Resource Identifiers (RRIDs) in publications for antibody traceability .

These challenges mirror broader issues in antibody reproducibility that cost research communities an estimated $0.4-1.8 billion annually in the United States alone .

How can advanced imaging techniques enhance YPL185W localization studies?

Advanced imaging approaches offer powerful enhancements for YPL185W localization studies:

• Super-resolution microscopy techniques:

  • Stimulated Emission Depletion (STED) microscopy can resolve structures below 50 nm.

  • Stochastic Optical Reconstruction Microscopy (STORM) provides ~20 nm resolution.

  • These techniques can distinguish between adjacent organelles or protein clusters impossible to resolve with conventional microscopy.

• Live-cell imaging approaches:

  • Combine YPL185W antibody fragments with cell-penetrating peptides.

  • Track dynamic localization changes during cell cycle or stress responses.

  • Correlate protein movement with cellular events in real-time.

• Multi-color co-localization analysis:

  • Simultaneously visualize YPL185W with organelle markers.

  • Calculate precise co-localization coefficients (Pearson's, Mander's).

  • Establish quantitative spatial relationships with other cellular components.

• Correlative Light and Electron Microscopy (CLEM):

  • Identify YPL185W localization by immunofluorescence.

  • Examine the same sample by electron microscopy for ultrastructural context.

  • Associate protein localization with specific subcellular structures at nanometer resolution.

These advanced imaging approaches provide more precise spatial information than the nuclear/cytoplasmic localization previously documented, potentially revealing microdomains or transient associations relevant to YPL185W function.

What emerging technologies might improve YPL185W antibody characterization in the future?

Several emerging technologies promise to enhance YPL185W antibody characterization:

• Knockout cell line validation platforms:

  • Systematic testing of antibodies against YPL185W knockout yeast strains.

  • Standardized protocols across Western blot, immunoprecipitation, and immunofluorescence.

  • Quantitative specificity scoring based on signal in wild-type versus knockout samples .

• Epitope mapping technologies:

  • High-resolution mass spectrometry for precise epitope identification.

  • Hydrogen-deuterium exchange methods to determine antibody binding sites.

  • Phage display epitope mapping for conformational epitopes.

  • These approaches provide more detailed information than current general localization data .

• Advanced recombinant antibody production:

  • Sequencing of hybridoma-produced antibodies for recombinant conversion.

  • CRISPR-based platforms for antibody engineering.

  • Synthetic biology approaches for antibody optimization .

• Publicly accessible characterization databases:

  • Centralized repositories of antibody validation data.

  • Community-contributed performance metrics across applications.

  • Standardized reporting formats with quantitative assessments .

These technologies align with initiatives like YCharOS and other antibody characterization efforts, which have demonstrated that approximately 50-75% of proteins are covered by at least one high-performing commercial antibody .